Patents by Inventor Stavros SELEMIDIS

Stavros SELEMIDIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATMENT
    Publication number: 20220213143
    Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 7, 2022
    Inventors: Stavros SELEMIDIS, Doug A. BROOKS, John O'LEARY
  • Method of treatment
    Patent number: 11319343
    Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: May 3, 2022
    Assignees: ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY, UNIVERSITY OF SOUTH AUSTRALIA, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEEN ELIZABETH NEAR DUBLIN, MONASH UNIVERSITY
    Inventors: Stavros Selemidis, Doug A. Brooks, John O'Leary
  • A METHOD OF TREATMENT
    Publication number: 20200216494
    Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.
    Type: Application
    Filed: June 29, 2018
    Publication date: July 9, 2020
    Inventors: Stavros SELEMIDIS, Doug A. BROOKS, John O'LEARY